Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
H-ferritin (FTH1) is the heavy chain subunit of the iron-storage protein ferritin, which plays a central role in cellular iron homeostasis by sequestering and detoxifying intracellular iron. In oncology research, H-ferritin is investigated as a diagnostic probe and a targeted delivery vehicle due to its specific internalization by various cancer cells, including glioblastoma, through receptors such as TIM-1 (T-cell immunoglobulin and mucin domain-containing protein 1). Preclinical studies utilize radiolabeled H-ferritin (e.g., with Iodine-125) to track iron acquisition mechanisms and tumor localization. Its ability to cross the blood-brain barrier and its natural uptake by malignant cells make it a candidate for both imaging and therapeutic applications in neuro-oncology.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on H-ferritin.